ERUCOV-VAC
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | ERUCOV-VAC |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
TURKOVAC (pronunciation: ['tɜ:rkəvæk]) (temporarily named as ERUCOV-VAC) is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.[1][2]
References[edit]
- ^ "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)". clinicaltrials.gov. United States National Library of Medicine. 31 December 2020. Retrieved 21 March 2021.
- ^ "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19". clinicaltrials.gov. United States National Library of Medicine. 30 March 2021. Retrieved 4 April 2021.
 |
Scholia has a profile for ERUCOV-VAC (Q106532118). |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |